Status:
UNKNOWN
Meclizine Plasma Levels in Responders and Non-responders
Lead Sponsor:
Medical Corps, Israel Defense Force
Conditions:
Seasickness
Meclizine
Eligibility:
All Genders
18-40 years
Phase:
PHASE4
Brief Summary
Motion sickness is a debilitating condition that can effect many crew members. Meclizine has long been known as an effective anti motion sickness drug. The response to the drug is variable - some are ...
Eligibility Criteria
Inclusion
- Seasickness questioner (WIKER) score of 7.
- Subjective functioning at 1 meter sea voyage - 5/10 and lower.
- Subjects who were prescribed 25mg of meclizine.
- Subjects who did not take any other drugs 48 prior to their participation in the study.
Exclusion
- Known hearing loss or any vestibular impairment
- Vertigo complains
- Any ear infection
- Use of Scopolamine based anti-seasickness drugs.
- Use of meclizine 50mg.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04482985
Start Date
September 1 2020
End Date
September 1 2021
Last Update
July 23 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.